Financial reports
10-K
2023 FY
Annual report
8 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
ARS
2023 FY
Annual report to shareholders
15 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
10-Q
2023 Q1
Quarterly report
5 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
Current reports
8-K
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
8 Mar 24
8-K
Regulation FD Disclosure
4 Mar 24
8-K
Regulation FD Disclosure
2 Feb 24
8-K
Other Events
3 Jan 24
8-K
Entry into a Material Definitive Agreement
26 Dec 23
8-K
Results of Operations and Financial Condition
14 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
13 Sep 23
8-K
Entera Bio Announces Q2 2023 Financial Results and Corporate Updates
11 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Jun 23
8-K
Other Events
27 Jun 23
Registration and prospectus
S-8
Registration of securities for employees
8 Mar 24
424B3
Prospectus supplement
15 Feb 24
S-3/A
Shelf registration (amended)
14 Feb 24
S-3
Shelf registration
2 Feb 24
D
$6.61 mm in equity / options / securities to be acquired, sold $6.61 mm, 52 investors
2 Jan 24
25-NSE/A
Exchange delisting (amended)
29 Jun 23
S-8
Registration of securities for employees
2 Jun 23
424B5
Prospectus supplement for primary offering
2 Sep 22
424B3
Prospectus supplement
10 Jun 22
424B3
Prospectus supplement
10 Jun 22
Other
EFFECT
Notice of effectiveness
15 Feb 24
CORRESP
Correspondence with SEC
14 Feb 24
EFFECT
Notice of effectiveness
10 Jun 22
EFFECT
Notice of effectiveness
10 Jun 22
CORRESP
Correspondence with SEC
7 Jun 22
CORRESP
Correspondence with SEC
7 Jun 22
UPLOAD
Letter from SEC
2 Jun 22
UPLOAD
Letter from SEC
2 Jun 22
EFFECT
Notice of effectiveness
23 Jul 20
CORRESP
Correspondence with SEC
20 Jul 20